Aridica Corporation is pleased to announce its selection for the 2025 BioTools Innovator Accelerator, the first and only program focused exclusively on life science tools and diagnostics companies. Chosen from over 400 applicants, Aridica Corporation is among just 31 startups to earn a spot in this year's prestigious cohort.
BioTools Innovator provides a four-month accelerator program offering tailored mentorship from senior industry leaders, investor exposure, and networking opportunities with peers and experts across the global life science community. At the end of the program, companies will compete for $300,000 in non-dilutive cash prizes.
Aridica Corporation was also selected to participate in the VANGUARD Accelerator, a joint initiative with BARDA to support companies advancing medical countermeasures for public health emergencies. VANGUARD is a joint initiative between BioTools Innovator and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
As part of the BioTools Innovator 2025 program, Aridica Corporation will participate in a series of events, including the Innovator Summit (June 24–26 in Mountain View, CA), pitch opportunities, and a final Capstone Event where companies will compete for a share of $300,000 in non-dilutive funding.
“We are honored to be recognized among the most promising innovators in life science tools and diagnostics. This opportunity will help us accelerate the development and commercialization of our PBMC separation platform. We're excited to engage with industry mentors and connect with peers as part of the BioTools Innovator ecosystem.”
About Aridica Corporation
Aridica Corporation is a life science tools innovator dedicated to advancing immunology research through its proprietary automated PBMC separation platform. By eliminating the inefficiencies of manual processing, Aridica empowers researchers with reliable, scalable solutions that accelerate discovery and development in oncology, immunology, infectious diseases, and advanced therapies. Based in Boulder, CO, Aridica is committed to enabling breakthrough science that improves patient outcomes.